Drilon: Next Senate can still use draft report on Pharmally probe
Senate Minority Leader Franklin Drilon on Monday said the next Senate in the 19th Congress can still adopt the Senate Blue Ribbon Committee’s findings on the investigation into Pharmally Pharmaceutical Corp.
Drilon pointed this out as he reiterated that the Pharmally investigation “is not a waste of time.”
Presently, the draft committee report prepared by Sen. Richard Gordon, chair of the blue ribbon panel, has yet to be filed due to lack of signatures from senators.
“It is not certainly a waste of time. Even if no committee report can be supported by the majority, then we exposed the anomalies which I am sure has put people on notice this should not be repeated,” Drilon said in an interview with reporters.
“So even if no committee report is filed, that is already the effect of that investigation. So it is not a waste of time,” he stressed.
According to Drilon, the records of the blue ribbon committee of the 18th Congress can be used as records of the 19th Congress.
“Not everything will go to waste because they can utilize the evidence gathered,” the minority leader stressed.